The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Novel immunotherapies transforming R/R myeloma treatment: bispecifics, CAR-T cells & more
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy, discusses the novel generation of recently approved and in-trial immunotherapies being explored for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Cerchione elaborates on trials involving novel bispecific antibodies such as teclistamab, elranatamab and alnuctamab, as well as CAR-T therapies such as ciltacabtagene autoleucel (cilta-cel), idecabtagene vicleucel (ide-cel), and academic CARs. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
